{"filings":[{"id":1508156,"accession_number":"0001193125-26-297992","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-07-08T11:17:42+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aura Biosciences appoints Jeremy Bender to Board of Directors; updates director compensation policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Bender, Ph.D., M.B.A., appointed as Class II director effective July 7, 2026; term expires at 2029 annual meeting.","Bender appointed to Compensation Committee and Nominating and Corporate Governance Committee.","Received initial option award for 60,000 shares and RSU award for 30,000 shares, vesting over three years.","Board amended Non-Employee Director Compensation Policy on June 11, 2026, increasing initial option award from 34,000 to 60,000 shares and annual option award from 17,000 to 30,000 shares.","Bender previously CEO of Day One Biopharmaceuticals, led acquisition by Servier for ~$2.5B in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000956,"accession_number":"0001193125-26-267676","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-06-11T20:31:01+00:00","items":["5.07"],"status":"ready","headline":"Aura Biosciences stockholders elect directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Johnson elected Class II director with 34,542,193 votes for, 6,628,297 withheld.","Teresa Marie Bitetti elected Class II director with 40,526,332 votes for, 644,158 withheld.","Ratification of Ernst & Young as auditor passed with 52,752,601 for, 17,348 against, 14,795 abstentions.","Total shares present or represented: 52,784,744 out of 64,199,778 eligible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12931,"accession_number":"0001193125-26-216743","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-05-11T20:05:34+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.","Phase 3 CoMpass trial in early choroidal melanoma enrollment expected to complete mid-2026; topline data in 2H 2027.","Natalie Holles appointed CEO and President effective April 30, 2026, succeeding founder Elisabet de los Pinos.","Completed $299M equity offering (net ~$280.8M); used $39M to repurchase shares from Matrix Capital; cash into 2H 2028.","Pipeline: Phase 2 choroidal metastases data in 2026; Phase 1 ocular cancer PoC data in 2026; bladder cancer data mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93238,"accession_number":"0001193125-26-206804","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aura Biosciences raises ~$280.8M in public offering; to repurchase $39M in stock from Matrix Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 39,591,000 shares at $6.00 and 3,800,000 pre-funded warrants, net proceeds ~$280.8M.","Underwriters' option for additional 6,508,650 shares exercised in full.","$241.8M to advance clinical programs including bel-sar and early choroidal melanoma.","$39M to repurchase 6,922,870 shares from Matrix Capital at $5.64 per share.","Cash runway extended into second half of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93237,"accession_number":"0001193125-26-204049","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","2.02","8.01"],"status":"ready","headline":"Aura Biosciences to repurchase ~6.9M shares from Matrix Capital at $5.64; reports preliminary cash of $114.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters stock purchase agreement to repurchase up to 6,922,870 shares from Matrix Capital Master Fund at $5.64 per share, matching equity offering price.","Repurchase conditioned on closing of equity offering; expected after offering closing. Matrix held 10.8% of outstanding shares pre-transaction.","Preliminary cash, cash equivalents, and marketable securities as of March 31, 2026: approximately $114.7 million (unaudited).","Repurchase funded by net proceeds from equity offering exceeding $200M; shares become authorized but unissued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93236,"accession_number":"0001193125-26-202414","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Aura Biosciences names Natalie Holles CEO; CoMpass trial enrollment at 86 patients, nearing completion","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New CEO Natalie Holles, former CEO of Third Harmonic Bio and Audentes, appointed effective April 30, 2026.","Founder Elisabet de los Pinos steps down as CEO and director; remains as consultant through October 2026.","Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has 86 patients enrolled; >25 additional patients identified for screening.","Company reiterates guidance: enrollment completion by mid-2026, topline data in H2 2027.","ATM prospectus terminated; $6.7M gross proceeds raised from 1.06M shares sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104683,"accession_number":"0001193125-26-130383","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences reports 2025 net loss $106.2M; Phase 3 CoMpass enrollment to complete mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $144.2M as of Dec 31, 2025; sufficient to fund operations into Q1 2027.","Phase 3 CoMpass trial enrollment completion expected by mid-2026; topline data in 2H 2027.","Phase 1b/2 NMIBC trial initial 3-month clinical data on track for mid-2026.","New formulation for non-ocular solid tumors achieved 12-month stability; patent filed for coverage into 2046.","Net loss for 2025 was $106.2M vs $86.9M in 2024; R&D expenses increased to $90.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120984,"accession_number":"0001193125-25-278810","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences Q3 net loss $26.1M; Phase 3 CoMpass data expected Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.1M in Q3 2025 vs $21.0M in Q3 2024; R&D expenses rose to $22.2M from $17.0M.","Cash and marketable securities $161.9M; cash runway into first half 2027.","Phase 3 CoMpass trial in early choroidal melanoma: enrollment completion expected 2026, topline data Q4 2027.","Phase 1b/2 NMIBC trial on track for initial data mid-2026; immune profiling shows cold-to-hot tumor conversion.","First patient dosed in Phase 2 choroidal metastases trial; entry criteria expanded to include all solid tumors."],"consensus_eps_estimate":-0.4758,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137584,"accession_number":"0001193125-25-179418","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences Q2 2025 net loss $27.0M; cash $177.3M; Phase 3 CoMpass nearing enrollment end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.0M in Q2 2025 vs $20.3M in Q2 2024; R&D expenses rose to $22.9M from $16.9M.","Cash and marketable securities $177.3M; $75M equity financing closed; cash runway into first half 2027.","Phase 3 CoMpass trial in early choroidal melanoma actively enrolling; >240 patients pre-screened; enrollment may complete by end of 2025.","Phase 1b/2 NMIBC trial actively enrolling; new bel-sar formulation patent filed for convenient in-office use.","Phase 2 trial in metastases to choroid protocol amended to include all solid tumors; initial data expected 2025."],"consensus_eps_estimate":-0.4667,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154950,"accession_number":"0000950170-25-087885","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aura Biosciences stockholders elect two Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elisabet de los Pinos re-elected with 28,961,014 votes for, 985,262 withheld, 8,917,095 broker non-votes.","Giovanni Mariggi re-elected with 29,179,073 votes for, 767,203 withheld, 8,917,095 broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025: 38,623,566 for, 232,989 against, 6,816 abstain.","Annual Meeting held June 17, 2025; 38,863,371 shares represented out of 50,268,758 entitled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154949,"accession_number":"0001193125-25-121677","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aura Biosciences closes $69.9M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 11.7M shares, 3.6M pre-funded warrants, and 3.8M common stock warrants at $4.90 combined price.","Net proceeds of approximately $69.9 million after underwriting discounts and expenses.","Proceeds to advance clinical programs in choroidal melanoma, ocular surface cancers, and bladder cancer.","Cash runway extended into the first half of 2027.","Offering closed on May 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154948,"accession_number":"0000950170-25-071839","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Aura Biosciences Q1 net loss $27.5M; appoints Tony Gibney as CFO; Phase 3 CoMpass enrollment may complete by end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.5M for Q1 2025 vs $19.7M in Q1 2024; R&D expenses rose to $23.3M from $17.1M.","Cash and marketable securities $128.0M as of March 31, 2025; runway into second half of 2026.","Appointed Tony Gibney as Chief Financial and Business Officer effective May 13, 2025; he brings 30+ years biotech and investment banking experience.","Phase 3 CoMpass trial in early-stage choroidal melanoma actively enrolling; enrollment may complete as early as end 2025.","First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in NMIBC; initial data at 3 months expected by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154947,"accession_number":"0000950170-25-048880","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aura Biosciences appoints Teresa Bitetti to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Teresa Bitetti appointed as Class II director effective March 31, 2025, filling newly created vacancy.","Bitetti is President of Global Oncology at Takeda; also appointed to Compensation Committee.","Received initial stock option for 29,000 shares and RSU for 21,000 shares, vesting over 3 years.","Board size increased from six to seven directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173460,"accession_number":"0000950170-25-043809","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences Q4/FY2024 results: net loss $86.9M, cash $151.1M, Phase 3 CoMpass actively enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $86.9M in FY2024 vs $76.4M in FY2023; R&D expenses $73.3M.","Cash $151.1M as of Dec 31, 2024; runway into 2H 2026.","Phase 3 CoMpass trial actively enrolling; >175 patients pre-screened globally since June 2024.","Phase 2 trial in choroidal metastases initiated; initial data expected 2025.","Phase 1 NMIBC data showed clinical complete responses; Tony Gibney appointed Senior Finance and Strategy Advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190451,"accession_number":"0000950170-24-125390","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences Q3 net loss $21M; cash $174.4M; Phase 3 CoMpass authorized in Europe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.0M (Q3 2024) vs $18.5M YoY; cash $174.4M funds operations into 2H 2026.","Phase 2 end-of-study: 80% tumor control, 90% visual acuity preservation in early-stage choroidal melanoma.","Phase 3 CoMpass trial authorized to enroll in Europe; >100 patients pre-screened globally.","Phase 1 NMIBC: 4/5 low-grade clinical complete responses; immune activation field effect observed.","Appointed Sabine Brookman-May as SVP, Therapeutic Area Head Urologic Oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190450,"accession_number":"0001193125-24-238959","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aura Biosciences: 4 of 5 low-grade NMIBC patients achieve clinical complete response with single-dose bel-sar","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of bel-sar in NMIBC: 4 of 5 low-grade patients had complete response (no tumor cells on histopathology).","2 of 3 high-grade patients showed visual tumor shrinkage on cystoscopy; immune activation observed in all evaluable patients.","Safety: only Grade 1 drug-related AEs in <10% of patients; no serious adverse events reported as of Sept 9, 2024 cutoff.","Evidence of bladder urothelial field effect in non-target tumors, suggesting broader immune response.","Company plans to expand Phase 1 and prepare for Phase 2 trial to evaluate durability of response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206951,"accession_number":"0001193125-24-227950","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Julie Feder to depart Oct 25; VP Finance Amy Elazzouzi named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Julie Feder will resign effective Oct 25, 2024; no dispute or disagreement with company.","Feder will provide consulting services through Dec 31, 2024, and receive severance of 10 months base salary.","Amy Elazzouzi, VP Finance, appointed interim principal financial and accounting officer effective Oct 25.","Elazzouzi's annual base salary increased to $360,000; eligible for 30% target bonus.","Company will search for a permanent CFO during the interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206950,"accession_number":"0001193125-24-217619","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aura reports positive Phase 2 bel-sar results: 80% tumor control, 90% vision preservation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bel-sar achieved 80% tumor control rate in Phase 3-eligible patients (8/10); complete cessation of growth post-treatment.","Visual acuity preserved in 90% of 10 patients; 80% had high-risk tumors near fovea/optic disc.","No treatment-related serious adverse events; mild Grade 1 ocular AEs self-limited, resolved in median 6 days.","FDA agreed under Special Protocol Assessment for Phase 3 CoMpass trial; enrollment ongoing.","Virtual investor event today at 8:00 am ET featuring key opinion leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206949,"accession_number":"0000950170-24-093298","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences reports Q2 2024 net loss of $20.3M; cash $187.4M into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.3M in Q2 2024 vs $18.3M in Q2 2023; R&D spend $16.9M, G&A $5.9M.","Cash and marketable securities $187.4M as of June 30, 2024; expected to fund operations into H2 2026.","Phase 3 CoMpass trial for small choroidal melanoma continues enrollment globally; target ~100 patients.","Early NMIBC Phase 1 data expected at virtual urologic oncology event in October 2024.","Phase 2 end-of-study data in small choroidal melanoma at Retina Society Annual Meeting Sept 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224236,"accession_number":"0001193125-24-165656","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Aura Biosciences shareholders approve officer exculpation amendment, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Tenth Amended Certificate limits officer liability per Delaware law; effective June 20, 2024.","Directors Antony Mattessich (28.3M for) and Sapna Srivastava (31.9M for) re-elected as Class III directors.","Ernst & Young ratified as independent auditor for FY 2024 with 38.7M votes for, 5,843 against.","Charter amendment filed as Exhibit 3.1; all proposals passed with broker non-votes on first two items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224235,"accession_number":"0001193125-24-154364","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aura Biosciences updates corporate deck for Jefferies conference; no material new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company conducting investor meetings at Jefferies Global Healthcare Conference starting June 5, 2024.","Updated corporate presentation filed as Exhibit 99.1; no specific financial or clinical updates disclosed.","No changes to guidance, pipeline milestones, or regulatory timelines announced.","Presentation includes forward-looking statements referencing risks in prior SEC filings.","Event is routine conference participation; no earnings or business combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224234,"accession_number":"0000950170-24-056252","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences Q1 2024 net loss $19.7M; cash $202.9M funds into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.7M for Q1 2024 vs $17.5M in Q1 2023; R&D spend $17.1M (up from $14.4M).","Cash and marketable securities $202.9M as of March 31, 2024; expected to fund operations into H2 2026.","Phase 3 CoMpass trial for small choroidal melanoma enrolling globally; target ~100 patients.","Phase 1 bladder cancer trial enrolling; early data expected mid-2024; Fast Track designation from FDA.","Appointed Conor Kilroy as General Counsel and Secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224233,"accession_number":"0001193125-24-096204","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Raj Parekh to resign from Aura Biosciences board effective June 20, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raj Parekh, Ph.D. notified Aura of his resignation from the board.","Resignation effective June 20, 2024, the date of the 2024 annual meeting.","Dr. Parekh's decision did not result from any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243581,"accession_number":"0000950170-24-036811","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences reports FY2023 net loss $76.4M; Phase 3 CoMpass trial enrolling with FDA SPA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $226.2M as of Dec 31, 2023; expected to fund operations into H2 2026.","Net loss $22.1M Q4 2023 and $76.4M full year 2023 vs $16.6M and $58.8M prior year.","R&D expenses $65.2M for FY2023, up from $42.2M due to Phase 3 start and manufacturing costs.","Global Phase 3 CoMpass trial for small choroidal melanoma actively enrolling under FDA SPA; Phase 2 showed 80% tumor control, 90% vision preservation.","Phase 1 bladder cancer trial ongoing; data expected mid-2024; first patient showed complete response after single dose with light activation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243580,"accession_number":"0001193125-24-003887","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aura Biosciences updates corporate presentation for J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company conducting investor meetings at 42nd Annual J.P. Morgan Healthcare Conference starting January 8, 2024.","Updated corporate presentation furnished as Exhibit 99.1; no specific financial or pipeline updates disclosed in the filing.","Presentation contains forward-looking statements; risks detailed in prior SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260995,"accession_number":"0000950170-23-062074","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Aura Biosciences raises $99M in public offering; Q3 net loss $18.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Closed underwritten public offering of 11M shares at $9.00/share, gross proceeds $99.0M; net proceeds ~$92.6M.","Cash and securities $149.1M as of Sept 30, 2023; combined with offering proceeds, cash runway into H2 2026.","Q3 2023 net loss $18.5M vs $15.9M YoY; R&D expenses $15.4M (up from $11.3M) driven by Phase 2/3 trial costs.","Positive Phase 2 data for bel-sar in choroidal melanoma: 80% tumor control, 90% visual acuity preservation at 12 months.","FDA agreed under SPA for Phase 3 CoMpass trial design; first patient dosing expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260994,"accession_number":"0001193125-23-271351","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aura Biosciences Receives FDA SPA Agreement for CoMpass Phase 3 Trial of Bel-sar in Choroidal Melanoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed under Special Protocol Assessment to design and planned analysis of CoMpass Phase 3 trial for bel-sar in early-stage choroidal melanoma.","Phase 2 data with 90% follow-up at 12 months showed 80% tumor control and 90% visual acuity preservation in patients meeting Phase 3 criteria.","Preliminary Phase 1 bladder cancer data: first patient with light activation achieved clinical complete response with extensive necrosis and immune activation.","Company terminated ATM equity offering program with Jefferies, suspending sales under existing prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260993,"accession_number":"0001193125-23-249055","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aura Biosciences names new CMO/President of R&D and CTO; CMO Rich transitions to advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Jill Hopkins appointed CMO and President of R&D, effective Oct 16, 2023; prior roles at Novartis, Gyroscope, Roche-Genentech.","Mark Plavsic appointed CTO; 30 years experience including Fate Therapeutics, Sanofi Genzyme, AstraZeneca.","Cadmus Rich resigns as CMO effective Oct 16; will serve as Senior Clinical Advisor through Nov 7, then consultant for 9 months.","Hopkins receives annual base salary of $525k, sign-on bonus up to $200k, and equity grants of 200k options and 135k RSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278257,"accession_number":"0000950170-23-040136","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences Q2 net loss $18.3M; cash $162M; Phase 3 trial on track for H2 2023 dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.3M vs $13.5M in Q2 2022; R&D expenses rose to $15.1M on Phase 3 start-up.","Cash and marketable securities $162.0M; expected to fund operations into H2 2025.","Phase 3 trial of bel-sar for choroidal melanoma enrolling; first patient dosing expected H2 2023; commercial material released.","Key leadership appointments: Bruce Brown (Urologic Oncology), Anthony Daniels (Ocular Oncology), Richard Mountfield (SVP Regulatory).","Phase 1 NMIBC trial ongoing; data expected 2024; Plan Phase 2 in choroidal metastasis in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296371,"accession_number":"0001193125-23-162617","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aura Biosciences shareholders elect David Johnson and Karan Takhar as directors, ratify EY auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At the annual meeting on June 7, 2023, shareholders elected David Johnson and Karan Takhar as Class II directors until 2026, with over 13.2 million votes for each.","The appointment of Ernst & Young as independent auditor for fiscal year 2023 was ratified with 25,725,525 votes for, 3,721 against, and 1,826 abstentions.","Broker non-votes on director elections totaled 9,206,963; there were no broker non-votes on auditor ratification.","Total shares present or represented were 25,731,072 out of 37,800,102 entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296370,"accession_number":"0000950170-23-021284","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences reports Q1 2023 net loss of $17.5M; FDA backs Phase 3 trial design for choroidal melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and marketable securities $173.5M as of March 31, 2023; cash runway into 2025.","Net loss $17.5M for Q1 2023 vs $12.8M in Q1 2022; R&D expense $14.4M (up from $8.3M).","FDA Type C meeting supports global Phase 3 trial (≈100 patients, 2:1:2 randomized) for early-stage choroidal melanoma.","Phase 2 enrollment complete; updated interim data expected 2H 2023; Phase 1 NMIBC data also due 2H 2023.","Appointed Patrick Nealon as SVP, Clinical Development Operations to lead late-stage development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296369,"accession_number":"0001193125-23-090316","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aura Biosciences COO Mark De Rosch resigns effective April 30, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Mark De Rosch resigns, effective April 30, 2023.","De Rosch to provide transition services for 30 days, extendable by another 30 days at Company's option.","No successor named as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316845,"accession_number":"0000950170-23-008163","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences Q4/Full Year 2022 Net Loss $58.8M; Phase 3 Trial on Track, FDA Fast Track for Choroidal Metastasis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $58.8M for FY2022 vs $35.3M in 2021; cash & securities $188.8M sufficient into 2025.","FDA granted Fast Track Designation for bel-sar in choroidal metastasis, second ocular oncology indication.","Global Phase 3 trial in early-stage choroidal melanoma on track to dose first patient in 1H 2023.","Positive interim Phase 2 data: 100% tumor control rate, statistically significant reduction in growth rate (p<0.0001) at 9-month follow-up.","Raised $92.5M gross proceeds in oversubscribed follow-on public offering in December 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316844,"accession_number":"0001193125-23-040742","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Phase 2 interim data: 100% tumor control, 88% vision preservation with bel-sar in early choroidal melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% tumor control (8/8) and 88% visual acuity preservation in patients receiving three cycles of bel-sar.","Statistically significant reduction in tumor growth rate: -0.289 mm/yr (p<0.0001) vs. each patient's documented rate.","No treatment-related SAEs; only mild anterior inflammation (Grade 1) in 20% of patients.","Company plans to initiate global Phase 3 trial enrollment this year based on these data.","Data presented at Macula Society 46th Annual Meeting with average 9 months follow-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316843,"accession_number":"0001193125-23-003670","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aura Biosciences updates corporate presentation for J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Attending 41st Annual J.P. Morgan Healthcare Conference starting January 9, 2023 in San Francisco.","Updated corporate presentation filed as Exhibit 99.1 for investor meetings.","Forward-looking statements caution about risks including clinical trials and regulatory approvals.","Company's product candidate belzupacap sarotalocan for choroidal melanoma is highlighted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335095,"accession_number":"0001193125-22-298535","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aura Biosciences raises $86.7M in public offering of 7.7M shares at $12.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds of ~$86.7M from 7.705M shares (including full overallotment) at $12.00 per share.","Proceeds to advance belzupacap sarotalocan for choroidal melanoma and NMIBC, plus platform and corporate.","Management expects cash runway to fund operations into 2025.","Offering closed Dec 5, 2022; underwriters led by SVB Securities, Cowen, Evercore."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335094,"accession_number":"0001193125-22-295368","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aura Biosciences updates corporate presentation; no new material information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Aura Biosciences posted an updated corporate presentation for investor and analyst meetings as of November 30, 2022.","The presentation update does not include any new financial results, clinical trial data, or material business changes.","No specific numbers, dates, or events were provided in the filing text to analyze."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335093,"accession_number":"0000950170-22-024145","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aura Biosciences reports Q3 2022 net loss of $15.9M; initiates global Phase 3 trial for bel-sar in choroidal melanoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.9M for Q3 2022 vs $8.8M YoY; cash $111.5M sufficient into 2024.","Research & development expenses $11.3M (+77% YoY); G&A $4.8M (+92% YoY).","Global Phase 3 trial for bel-sar in early-stage choroidal melanoma initiated: 3-arm, masked, ~75 patients, adaptive design.","Positive Phase 2 interim data: tumor growth rate reduction (p=0.0007), 88.9% tumor control rate, favorable safety.","First patient dosed in Phase 1 for NMIBC; initial data expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335092,"accession_number":"0001193125-22-256110","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aura reports Phase 2 interim data: 89% tumor control, significant growth rate reduction for choroidal melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim Phase 2 data for belzupacap sarotalocan (AU-011) in early-stage choroidal melanoma show 88.9% (8/9) tumor control rate at therapeutic regimen.","Statistically significant reduction in tumor growth rate of -0.296 mm/year (p=0.0007) vs. documented historical growth.","Visual acuity preservation rate of 88.9% (8/9) in highest dose cohorts; most tumors were near fovea or optic disc.","No dose-limiting toxicities or treatment-related serious adverse events reported; mild anterior inflammation in 20%.","Data support planned pivotal program; company held virtual investor day on October 3, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352536,"accession_number":"0001193125-22-252714","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-09-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aura Biosciences doses first patient in Phase 1 study of AU-011 for bladder cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 study of belzupacap sarotalocan (AU-011) for non-muscle invasive bladder cancer (NMIBC).","Phase 1 open-label trial to enroll approximately 23 adults; primary endpoint safety/tolerability.","Initial Phase 1 data expected in 2023; CMO notes no major advances in NMIBC in over two decades.","FDA granted Fast Track designation for AU-011 in NMIBC in June 2022.","Approximately 70% of bladder cancer patients are diagnosed early with NMIBC (global)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352535,"accession_number":"0000950170-22-016905","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences Q2 2022 net loss $13.5M; cash $122.1M; NMIBC trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.5M for Q2 2022 vs $8.9M in Q2 2021; R&D expense rose to $9.5M from $6.6M.","Cash and equivalents $122.1M; sufficient to fund operations into 2024.","On track to dose first patient in Phase 1 NMIBC trial in Q3 2022; FDA Fast Track granted.","On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.","Plans to file IND for choroidal metastases in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370097,"accession_number":"0001193125-22-185580","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aura Biosciences receives FDA Fast Track for belzupacap sarotalocan in NMIBC; Phase 1 trial H2 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation for belzupacap sarotalocan (AU-011) for treatment of Non-Muscle Invasive Bladder Cancer.","NMIBC has no approved targeted therapies; high recurrence and progression often leading to cystectomy.","Aura plans Phase 1 trial in NMIBC starting H2 2022, with initial data expected in 2023.","AU-011 previously received Fast Track and Orphan Drug designations for choroidal melanoma, currently in Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370096,"accession_number":"0001193125-22-178857","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aura Biosciences reports positive retrospective data for AU-011 in choroidal melanoma vs. radiotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Belzupacap sarotalocan showed statistically significant vision preservation at 2 years vs. plaque radiotherapy (logMAR p=0.0094).","Radiotherapy patients lost ≥3 lines of vision in a majority by 2 years; ≥6 lines by 3 years.","Data from 43 AU-011 patients vs. 150 matched radiotherapy controls (tumor edge within 3.0 mm of fovea).","Mean follow-up for AU-011 was 15.6 months; study is retrospective and hypothesis-generating.","Phase 2 trial (suprachoroidal) ongoing; pivotal trial expected to initiate by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370095,"accession_number":"0001193125-22-174863","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aura Biosciences shareholders elect three Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elisabet de los Pinos, Giovanni Mariggi, Raj Parekh elected as Class I directors with ~18.4M+ votes each.","Ernst & Young ratified as independent auditor for FY2022; 19,088,824 for, 604 against, 1,963 abstentions.","Total shares present or represented: 19,091,391 out of 29,222,296 eligible shares.","No other proposals or material items were voted on at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370094,"accession_number":"0001193125-22-161235","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aura Biosciences publishes preclinical data on AU-011 + checkpoint inhibitors at ASCO 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AU-011 combined with immune checkpoint inhibitors showed efficacy against primary tumors and distant metastases in murine models.","Data published as abstract e14544 in 2022 ASCO Annual Meeting proceedings (June 3-7, 2022).","Collaboration with Leiden University Medical Center: survival data suggest potent targeted cytotoxicity on local tumors and metastases.","Potential clinical application for choroidal melanoma and non-muscle invasive bladder cancer (NMIBC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370093,"accession_number":"0001193125-22-154031","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Aura Biosciences signs 10-year lease for 29,836 sq ft office/lab space in Brighton, MA; annual base rent ~$3.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for ~29,836 sq ft at 80 Guest Street, Brighton, MA; term 10 years from Aug 1, 2022.","Annual base rent ~$3.1M first year, increasing ~3% annually plus costs/taxes/opex.","One 7-year extension option; security deposit via $0.77M standby letter of credit.","Company will occupy office and laboratory space for new principal corporate offices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370092,"accession_number":"0000950170-22-009706","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences Q1 2022 net loss $12.8M; cash $133.3M; AU-011 pivotal trial in 2H 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.8M in Q1 2022 compared to $5.9M in Q1 2021; cash and marketable securities $133.3M, sufficient into 2024.","R&D expenses $8.3M (up from $4.2M) and G&A $4.5M (up from $1.7M), driven by manufacturing and public company costs.","Plan to initiate pivotal trial for AU-011 in choroidal melanoma in 2H 2022; European Commission granted Orphan Drug Designation for uveal melanoma.","IND submission for choroidal metastases and Phase 1 trial in NMIBC expected in 2H 2022, with initial data in 2023.","Preclinical data at ASCO and AACR show AU-011's broad tumor targeting and combination potential with checkpoint inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389213,"accession_number":"0000950170-22-004419","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences reports FY2021 net loss $35.3M; cash $149.1M into 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2021 was $35.3M, up from $22.2M in FY2020; R&D expenses rose to $25.2M.","Cash and equivalents totaled $149.1M at Dec 31, 2021; runway into 2024.","On track to initiate pivotal trial in choroidal melanoma and Phase 1 in NMIBC in 2H 2022.","European Commission granted Orphan Drug Designation for AU-011 in uveal melanoma.","John Maraganore, former Alnylam CEO, joins as strategic advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407118,"accession_number":"0000950170-21-004906","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2021-11-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aura Biosciences Q3 net loss $8.8M; AU-011 data and IPO highlight quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.8M for Q3 2021 vs $3.6M YoY; R&D expenses $6.4M (up from $2.9M).","Cash $81.8M at Sep 30; IPO raised $86.9M gross in Nov 2021 at $14.00/share.","Final Phase 1b/2 data: 64% tumor control, 71% visual acuity preservation for AU-011 in choroidal melanoma.","Plans to start AU-011 pivotal program H2 2022; Phase 1a in NMIBC expected H2 2022.","Added Antony Mattessich to board and Chris Primiano as CBO in September 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-77.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407117,"accession_number":"0001193125-21-316929","cik":1501796,"company_name":"Aura Biosciences, Inc.","ticker":"AURA","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aura Biosciences amends charter and bylaws upon IPO; authorizes 150M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized 150 million shares of common stock and 10 million shares of undesignated preferred stock.","Eliminated all references to prior series of preferred stock from charter.","Amended bylaws effective Oct 28, 2021: removed stockholder written consent and special meeting rights.","Established procedures for stockholder proposals and director nominations in bylaws.","All changes were previously disclosed in IPO registration statement S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":797110291.4412532,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-02T23:59:59+00:00|407117"}